Drug Profile
Famitinib - Jiangsu Hengrui Medicine
Alternative Names: Famitinib maleate; SHR 1020Latest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Fudan University; Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Diethylamines; Fluorobenzenes; Indoles; Pyrroles; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cervical cancer; Colorectal cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer
- Phase II Biliary cancer; Endometrial cancer; Fallopian tube cancer; HER2 negative breast cancer; Nasopharyngeal cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Thyroid cancer; Triple negative breast cancer; Urogenital cancer
- Phase I/II Osteosarcoma
- Clinical Phase Unknown Fibroma
- No development reported Breast cancer
Most Recent Events
- 09 Feb 2024 Jiangsu HengRui Medicine terminates phase III trial in Gastrointestinal stromal tumours (Inoperable/Unresectable, Late-stage disease) in China (PO) due to R&D business strategy (NCT04409223)
- 05 Dec 2023 Efficacy and adverse events data from a phase I/II trial in HER2-negative breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 28 Nov 2023 Ruijin Hospital plans a phase II trial for famitinib in Thyroid cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Combination therapy) (PO) in December 2023 (NCT06146985)